AUS
NZ
UK
CA
USA
IND
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biopharmaceutical company, announced that CEO and Chairman Robert Bitterman will deliver a presentation highlighting the company's proprietary INTASYL gene silencing technology platform during a Renmark Financial Communications virtual non-deal roadshow on Tuesday, July 28, 2026. The session will emphasize the lead clinical candidate PH-762, developed for treating cutaneous carcinomas, and will include a live Q&A with investors. This July 22, 2026 announcement corrects the previously stated day of the week for the event.
Key Points
- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) specializes in clinical-stage siRNA biopharmaceuticals targeting immuno-oncology therapies.
- CEO Robert Bitterman will present on July 28, 2026, at 12 PM EDT during the Renmark Virtual Non-Deal Roadshow Series.
- The presentation will focus on the INTASYL gene silencing platform and the lead candidate PH-762 for skin cancer treatment.
- A live Q&A session will follow, with a replay accessible on the Renmark Financial Communications website.
Clarification on Roadshow Event Date and Time
On July 22, 2026, Phio Pharmaceuticals issued a correction confirming that the corporate presentation will occur on Tuesday, July 28, 2026, at 12 PM Eastern Daylight Time. This update ensures investors have accurate information regarding the company's participation in the Renmark Financial Communications virtual non-deal roadshow series, including the live presentation and Q&A session.
Virtual non-deal roadshows are commonly used by clinical-stage biopharmaceutical firms to engage institutional investors and analysts, providing updates on pipeline programs, technology platforms, and strategic direction without the regulatory constraints of formal equity offerings or guidance revisions.
Focus on INTASYL Platform and Lead Candidate PH-762
The upcoming presentation will center on Phio's proprietary INTASYL siRNA gene silencing technology platform. INTASYL compounds are engineered to boost the immune system’s ability to target and destroy cancer cells, positioning Phio within the immuno-oncology sector, which has experienced significant investment and clinical progress in recent years.
Phio's lead clinical program, PH-762, is an INTASYL compound designed to silence the PD-1 gene implicated in multiple skin cancers. PH-762 is being developed as a potential non-surgical treatment for cutaneous carcinomas. A Phase 1b clinical trial (NCT# 06014086) has evaluated PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. CEO Robert Bitterman stated, "We look forward to engaging with investors at the Renmark Financial Virtual Non-Deal Roadshow and sharing our perspective on how INTASYL may offer a unique and promising approach to advancing immuno-oncology therapies."
Investor Participation and Registration Information
Investors interested in attending the live presentation can register via the Renmark Financial Communications registration portal. The company advises that if the registration link does not function correctly, users should copy and paste the URL into their web browser. For optimal connectivity during the virtual event, Phio and Renmark recommend using the latest version of Google Chrome.
A replay of the presentation and Q&A session will be available on the Renmark Financial Communications website after the live event, enabling investors unable to join in real time to access the content later. This replay option is standard in virtual investor relations events, broadening the reach of management’s insights beyond the live audience.
Clinical-Stage Pipeline and Technology Overview
Phio Pharmaceuticals is a clinical-stage biopharmaceutical company advancing therapeutic candidates through clinical trials without yet having regulatory approval for commercialization. The company is progressing its INTASYL siRNA gene silencing technology targeting oncology indications, with a strategic emphasis on skin cancers including squamous cell carcinoma, melanoma, and Merkel cell carcinoma, all addressed in the Phase 1b trial for PH-762.
RNA interference (RNAi) technology, such as the siRNA compounds in the INTASYL platform, represents a novel therapeutic modality by selectively silencing disease-related genes. Phio’s approach integrates gene silencing with immuno-oncology, distinguishing it within the broader RNAi therapeutic landscape.
CEO Robert Bitterman’s Role in Investor Engagement
Robert Bitterman, serving as CEO and Chairman of Phio Pharmaceuticals, will personally lead the presentation at the Renmark virtual roadshow. CEO involvement in investor communications highlights the company’s commitment to transparent dialogue with capital markets, especially when discussing early-stage clinical programs. This direct engagement allows senior leadership to address strategic inquiries and contextualize development priorities.
While the announcement quotes Bitterman on the potential of the INTASYL platform, the live Q&A session will offer investors the chance to question the CEO on clinical timelines, regulatory strategies, financial resources, and competitive positioning.
Company Background and Corporate Profile
Phio Pharmaceuticals Corp., headquartered in King of Prussia, Pennsylvania, trades on the NASDAQ under the ticker PHIO. The company identifies as a clinical-stage siRNA biopharmaceutical firm with a proprietary gene silencing platform aimed at eradicating cancer by enhancing immune responses.
The announcement includes standard forward-looking statements disclaimers, referencing detailed risk disclosures in Phio’s latest Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings provide comprehensive insights into the company’s financial health, operational status, and risk factors.
Context of Virtual Non-Deal Roadshows in Biopharma
Virtual non-deal roadshows are vital for clinical-stage biopharmaceutical companies to maintain investor engagement between formal clinical data releases or regulatory milestones. These events offer investors direct access to management’s strategic perspectives without the constraints of earnings calls or official guidance updates.
Phio’s July 2026 presentation occurs during the northern hemisphere summer, a period of typically reduced institutional investor activity. However, the virtual format eliminates geographic and logistical barriers, potentially increasing participation compared to in-person events. The availability of a replay further extends the event’s reach.
Forward-Looking Statements and Risk Factors
The announcement contains extensive forward-looking statements disclaimers, acknowledging inherent uncertainties in clinical-stage biopharmaceutical development. Factors such as FDA interactions, inflation, clinical trial outcomes, manufacturing capabilities, intellectual property, financing availability, and market conditions may cause actual results to differ materially. These risks are detailed in the company’s SEC filings.
Investors should note the forward-looking language regarding anticipated benefits of the INTASYL platform, ongoing clinical trial results, FDA submission expectations, and the company’s capacity to fund development with existing capital. Phio expressly disclaims any obligation to update forward-looking statements except as required by law.
Technical Guidance and Event Registration for Investors
Investors planning to attend the live presentation must register via the Renmark Financial Communications link provided. Phio advises using the latest Google Chrome browser version to ensure optimal connectivity and functionality during the virtual event, consistent with standard virtual platform requirements.
The announcement does not specify the presentation’s duration, expected participant numbers, or detailed Q&A format. Investors should consult the Renmark Financial Communications website or registration portal for additional logistical information.
